Breaking Down the 2026 AHA/ASA Acute Ischemic Stroke (AIS) Guidelines

What the 2026 AHA/ASA Acute Ischemic Stroke Guidelines Mean for Your Clinical Practice

March 4, 2026

Since the last major AHA acute ischemic stroke (AIS) guidelines were published, the field has been reshaped by landmark trials, the mainstreaming of advanced imaging, and the rapid expansion of telemedicine. The updated 2026 guidelines reflect all of that, and the clinical and operational implications are substantial.

On March 4, 2026, Adjacent Health convened a webinar to help clinicians cut through the density of this nearly 119-page document and focus on the biggest implications for patient care. Led by Dr. Chad Miller, CMO of Adjacent Health Solutions and board-certified neurologist, neurointensivist, and vascular neurologist, and Kim Warren, DNP, a stroke-certified registered nurse and Joint Commission disease-specific care reviewer with over 25 years of experience in stroke care, the session distilled the highest-impact changes into actionable clinical guidance that every clinician caring for stroke patients needs to know.

Pre-Hospital Care: EMS, Mobile Stroke Units, and Telemedicine Get a Major Upgrade

The guidelines open with strong statements about how patients reach definitive care. The first is an important clarification on bypass decisions: EMS should not bypass a TPA-capable hospital to reach a distant comprehensive stroke center (CSC) if that CSC is 45–60 minutes away, and a well-established transfer process exists. The emphasis remains on timely access to thrombolysis assessment and treatment.

Mobile stroke units, once a novelty, are now backed by Class I evidence. The BE-PROUD and BEST-MSU trials demonstrated that mobile stroke units increase the number of patients treated, reduce time to treatment, and improve 90-day outcomes. If your system has one, its protocols deserve a fresh look in light of these guidelines.

Telemedicine receives some of the strongest and most expansive language in the document. It is now recommended not just at primary stroke centers, but in the ambulance itself, even outside mobile stroke unit contexts, and particularly for identifying potential LVO patients. The guidelines are explicit: telemedicine evaluation by a stroke specialist is preferable to assessment by ED teams without stroke expertise. Data from the StrokeDOC trial and subsequent studies confirm that video consultation is more accurate than phone alone, and telemedicine-guided patient selection is at least equivalent to in-person assessment for treatment decisions.

Imaging: Faster, More Comprehensive, and No More Waiting on Labs

The target for completing initial imaging remains under 25 minutes from arrival — but the stakes are higher now given the expanded revascularization windows. Critically, multimodal imaging should never be delayed waiting for laboratory results. Creatinine clearance requirements for advanced imaging should be removed from your acute stroke order sets.

Extended Thrombolysis Windows: The Headline Change

This update has the field particularly energized. Patients in the 4.5- to 9-hour window may now be considered for IV thrombolysis, with patient selection based on CT perfusion (CTP) imaging — not just MRI. This extends eligibility beyond the institutions with emergent MRI capability, which is a significant equity win. The evidence base includes the EXTEND, TRACE-3, and TIMELESS trials, all using CTP-based mismatch criteria.

The wake-up stroke pathway based on MRI (no FLAIR change with DWI changes less than one-third MCA territory) remains valid. For patients 4.5–24 hours from onset with LVO who cannot access endovascular therapy, thrombolysis should be considered.

Key Thrombolysis Updates at a Glance

Tenecteplase and alteplase are now considered equivalent for adults. Weight-based dosing guides for Tenecteplase are acceptable to reduce preparation errors, though precise weight-based dosing remains appropriate and accurate.

Thrombolytic eligibility is based on disability, not NIH Stroke Scale score. The guidelines emphasize that what constitutes a “disabling” deficit is individual — and that stroke mimics should be strongly considered for treatment given their low complication rate. If you’ve corrected a patient’s hypo- or hyperglycemia and the presenting neurological deficit persists, the Class I recommendation is to proceed with thrombolysis.

The contraindication list has shrunk significantly. Many previously absolute contraindications — oral anticoagulant use, recent stroke, remote brain hemorrhage, prior surgery, history of bleeding — have shifted to relative contraindications, requiring individualized risk-benefit assessment and careful documentation. Absolute contraindications now include established large stroke, active brain hemorrhage, recent spinal surgery/trauma, intraaxial neoplasms (e.g., GBM), significant coagulopathy, and patients on amyloid immunotherapy (due to elevated hemorrhage risk from ARIA).

Blood pressure targets have been refined. Post-thrombolysis, the goal is less than 180 mmHg systolic — but tightly controlled BP below 140 mmHg is explicitly not recommended for the first 72 hours and may cause harm. The same parameters apply to endovascular patients with successful reperfusion.

Glycemic targets: Maintain blood glucose between 140–180 mg/dL. Avoid dropping below 130. Both hyper- and hypoglycemia worsen infarct volume, and overly aggressive glycemic control harms as many patients as it helps.

Endovascular Therapy: A Simplified Framework for Expanded Selection

The guideline’s endovascular algorithm is comprehensive — and admittedly complex. Dr. Miller offered a practical five-point framework that captures the Class I and Class IIa recommendations:

0–6 hours, ICA or M1 occlusion, good pre-stroke function (mRS 0–1): Treat with EVT even with significant early ischemic changes on CT. CTP is not required in this window.
0–6 hours, ICA or MCA occlusion, moderate pre-stroke disability (mRS 3–4): EVT can be considered, though benefit is less certain.
0–6 hours, dominant hemisphere M2 occlusion, good pre-stroke function: EVT is now recommended for significant disability — this is a new addition to guidelines.
0–24 hours, good pre-stroke function, significant deficit, favorable CT (ASPECTS ≥6): EVT is standard of care. Patients under 80 with ASPECTS 3–5 may also be considered.
0–24 hours, good pre-stroke function, substantial disability, vascular occlusion: EVT should be offered — this has long been clinical practice and now carries guideline-level backing.

Regarding technique: contact aspiration is now considered equivalent to stent retrieval, and combined approaches are endorsed. For posterior circulation strokes including basilar artery occlusion, EVT selection follows the same mRS, NIHSS, and ASPECTS framework.

Patients transferred to a CSC for EVT do not require repeat imaging unless there has been neurologic deterioration — get them to the table.

Inpatient Care and Secondary Prevention

The guidelines call for dedicated stroke units at primary stroke centers and above — not just dedicated beds. Evidence consistently shows that coordinated stroke unit care reduces variability, accelerates rehab initiation, and improves outcomes.

For secondary prevention:

Dual antiplatelet therapy (aspirin + clopidogrel) is recommended for mild stroke (NIHSS <5) and TIA those patients with atherosclerotic etiology — initiate immediately if thrombolysis was not given.
For clopidogrel non-responders (identified by platelet function testing), ticagrelor is the preferred alternative.
For cervical dissection, antiplatelets and anticoagulation are equivalent for at least three months.
Anticoagulation for high-grade non-occlusive intraluminal thrombi does not show benefit and carries meaningful risk — a notable departure from common practice.

Decompressive craniectomy for malignant MCA infarction carries Class IA evidence for patients 60 and under who deteriorate in the first 48 hours. Above 60, the functional benefit is significantly diminished.

The Clinical Imperative

The 2026 AIS guidelines represent one of the most substantive updates in stroke medicine in nearly a decade. They expand who we treat, when we treat, and how we treat — and they place renewed emphasis on the infrastructure, expertise, and coordination required to deliver that care reliably.

Adjacent Health’s Dr. Chad Miller and Kim Warren will continue supporting clients stroke programs as they navigate these changes. Whether your challenge is extending thrombolysis windows, building telemedicine workflows, or updating your EMR order sets, the path forward begins with understanding what has changed — and why it matters for every patient who comes through our doors.

To learn more about how Adjacent Health supports stroke programs across the care continuum, contact your account manager or reach out to our team directly.